# ALKAZAR (NCT06765109)

> Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06765109
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Nuvalent Inc.
- Conditions: Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive
- Interventions: Neladalkib (NVL-655); Alectinib
- Enrollment: 450
- Primary outcome: Progression-free survival (PFS) per blinded independent central review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 7
- X threads: 5
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=alkazar-nct06765109

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06765109", "email": "<work email>"}; the inbox owner confirms by the emailed link.